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corroborate the beneﬁts of PFN.
0667: HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY: AN AID TO
DIAGNOSIS
S.J. Khan*, B.D. Sarmah. Heart of England NHS foundation Trust, UK
Aim: The aim of this study was to evaluate if Hexaminolevulinate (Hexvix)
ﬂuorescence cystoscopy improved bladder tumour identiﬁcation and man-
agement andwhether repeated episodes ofHexvix incurred further beneﬁts.
Methods: All patients undergoing Hexvix cystoscopy at a District General
Hospital between October 2008 and October 2014 were incorporated. Data
collected and analysed included reason for Hexvix, repeats of Hexvix,
ﬁndings at white-light and Hexvix cystoscopies, complications, histology
and outcomes.
Results: Sixty cases of Hexvix cystoscopies were performed on forty-nine
patients. Nine had repeats and two had a further third episode. No
complications were reported. Reasons for Hexvix included thirty-eight
(63%) for surveillance/abnormal ﬂexible cystoscopy, ten (16.7%) post-BCG
treatment and ten (16.7%) persistently abnormal urine cytology. Twenty-
two (36.7%) conﬁrmed bladder carcinoma. Twenty-two cases docu-
mented white-light and Hexvix ﬁndings. Twelve described no abnor-
malities with white-light which ﬂuoresced using Hexvix. Of these, ﬁve
conﬁrmed malignancy. Three of nine patients conﬁrmed bladder malig-
nancies after the initial Hexvix. Subsequent repeats detected no
abnormalities.
Conclusion: Hexvix improved the detection of bladder tumours, particu-
larly in CIS/pT1G3 tumours. It highlighted areas of malignancies not
visualised by white-light cystoscopy. No additional beneﬁts were seen
from repeating Hexvix cystoscopies.
0680: META-ANALYSIS OF HOLMIUM LASER ENUCLEATION VERSUS
TRANSURETHRAL RESECTION OF PROSTATE FOR PATIENTS WITH
BENIGN PROSTATIC OBSTRUCTION
O. Naser 1,*, A. Negida 2, E. Kasem 2, A. Mokhtar 3, A. Menshawy 4, T.
Badawy 5, A.S. Turky 3, A. Tammam6, A. El-Sawaf 3, B. Gana 1. 1West
Wales General Hospital, UK; 2 Zagazig University, Egypt; 3Menouﬁa
University, Egypt; 4Azhar University, Egypt; 5Alexandria University, Egypt;
6Cairo University, Egypt
Aim: This meta-analysis aims at comparing Holmium laser enucleation
(HoLEP) versus transurethral resection of prostate (TURP) for patients with
benign prostatic obstruction.
Methods: PubMed was searched for RCTs comparing HoLEP versus TURP
using relevant search terms. Data were extracted from eligible studies
and were analyzed using RevMan 5.3 for windows. In case of multiple
reports for the same patients, we analyzed data from the most recent
dataset.
Results: Nine RCTs (871 patients) were included in the ﬁnal analysis.
Follow up ranged from 6 to 92 months. For perioperative outcomes, he-
moglobin loss (SMD¼-0.41, 95% CI¼[-0.60, -0.22]) and blood transfusion
(RR¼0.17, 95% CI¼[0.05, 0.65]) were less in HoLEP than TURP. For post-
operative outcomes, maximum ﬂow rate (SMD¼0.15, 95% CI¼[0.00, 0.29])
and post-void residual volume (SMD¼-0.27, 95% CI¼[-0.46, -0.08]) were
better in HoLEP than TURP. There was no difference in terms of IPSS
(SMD¼-0.01, 95% CI¼[-0.20, 0.19]), AUA symptom score (SMD¼-0.16, 95%
CI¼[-0.35, 0.02]) or QoL (SMD¼0.14, 95% CI¼[-0.06, 0.33]). The overall
relative risk of urethral strictures, incontinence and recatheterization did
not favor either of the two modalities.
Conclusion: HoLEP achieved better changes in Qmax and PVR than TURP.
Hemoglobin loss and perioperative blood transfusion were less in HoLEP
than TURP.
0757: A SERVICE IMPROVEMENT PROJECT FOR EMERGENCY
UROLOGICAL ADMISSIONS
T. Tharakan*, C. Wou, A. Phaily, W. Dunsmuir. Ashford and St Peter's
Hospital NHS Foundation Trust, UKAim: IncreasingA&Eattendances have resulted inmore emergency urology
referrals and subsequent admissions. At our Trust, the surgical senior house
ofﬁcer (SHO) is the gatekeeper for patients with possible urological prob-
lems. Our Trust has moved to a consultant-led service with loss of registrar
cover out-of-hours. A previous Trust audit concluded 29% of all emergency
urological admissions were inappropriate. The registrar timetable was
therefore reconﬁgured to extend their hours from 8pm to 10pm to support
the SHO. This re-audit reviewed admissions after these changes.
Methods: We retrospectively reviewed the notes of 77 patients who were
admitted under the urology team during one month and compared results
to the previous audit.
Results: Total preventable admissions dropped by 11%. Half of these ad-
missions could be managed at home. 72% of inappropriate admission were
admitted out-of-hours. Collectively, these patients stayed in hospital for a
total of 46 days. The total cost for these days is estimated to be over £15,000.
Conclusion: Improvements in registrar timetabling resulted in a 11%
decrease in inappropriate urological admissions, highlighting the impor-
tance of senior support and potential ﬁnancial savings. Further investiga-
tion into the causes of inappropriate admissions is required e.g. depth of
urological knowledge of admitting SHOs.0758: TIMING OF SECOND RESECTION IN HIGH-GRADE NON-MUSCLE-
INVASIVE BLADDER CANCER: DOES DELAY ADVERSELY AFFECT
OUTCOME?
J. Fitzpatrick, D.R. Biju*, T. Amer, R. Hutton, B. Nair. University Hospital Ayr,
UK
Aim: In non-muscle-invasive bladder cancer (NMIBC), there is a risk that
residual tumour may be present after initial resection and that the tumour
is under-staged. There is still debate regarding the optimum timing of
second resection although current guidelines advocate 2-6 weeks. The aim
was to determine whether delay to second resection adversely affects
disease outcomes in NMIBC.
Methods: This was a retrospective analysis of 56 patients with high-grade
(G3) NMIBC from 2005-2010 who underwent repeat resection following
initial TURBT. Data was collected from online databases.
Results: The majority of patients (61%; 34/56) had T1 disease. Out of 56
patients, 50% (28/56) had evidence of residual tumour on repeat resection;
14% (8/56) had been under-staged and 50% (4/8) of these had muscle-
invasive disease which altered treatment. During follow-up, 61% (34/56)
developed recurrence and 25% (14/56) disease progression. Time to second
resectionwas <6 weeks in 30% (17/56) and >6 weeks in 70% (39/56). There
was no signiﬁcant difference in recurrence (76%:54%, p¼0.11) or progres-
sion (35%:21%, p¼0.24) between these two groups.
Conclusion: We ﬁnd no signiﬁcant difference on adverse outcomes when
repeat resection is delayed beyond 6 weeks. Further research is required to
determine the optimum timing for repeat resection.0783: ASSESSMENT OF CLINICAL OUTCOMES OF ORTHOTOPIC NEO-
BLADDER RECONSTRUCTION AFTER RADICAL CYSTECTOMY
A. Anwar*, G.M. Nandwani, R. Singh, R. Chahal, S. Addla. Bradford Royal
Inﬁrmary, UK
Aim: In reconstructive urology orthotopic neobladder is the diversion of
choice. It does not compromise oncological outcome, yields excellent
functional results and cost effective compare to incontinent diversions.
Methods: 128 patients underwent radical cystectomy April 2009 till
October 2014. 109 ileal conduit and 19 had orthotopic neobladder recon-
struction(ONB). Data collected from hospital notes, electronic records.
Patients evaluation on functional outcomes (incontinence, infection, uri-
nary retention, self catheterisation, oncological outcomes (cancer free
survival(CSS), overall survival(OSS), cancer recurrence, pathological stag-
ing) and surgical complications (Clavien-Dindo).
Results: Total n¼19 ONB reconstruction (male¼16, female¼3), age 67 ± 21
years, 67%(n¼12) ASA-1, 37%(n¼7), duration of surgery 370 ± 110 minutes,
blood loss 700 ± 500 mls, Mortality(n¼1) secondary to chest infection. CSS
100%(n¼18) and OSS 94.7% at a median follow-up of 36 ± 14 months. Local
